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Objective: The objective of this selective EBM review is to determine whether or not 
collagenase injection decreases recurrence rates greater than percutaneous needle fasciotomy in 
the treatment of Dupuytren’s contracture. 
 
Study Design: A systematic review of three randomized control trials. 
 
Data Sources: The reviewed articles were written in English and published in peer-reviewed 
journals between 2016 and 2017. These articles were chosen based on their ability to answer the 
proposed question of this review and obtained through Cochran and PubMed databases. 
 
Outcomes Measured: Outcomes were measured by the recurrence of contractures, which is 
defined as passive extension deficits of 20-30 degrees post-treatment or requiring additional 
treatment after initial therapy. 
 
Results: Scherman et al. (J Hand Surg Eur Vol. 2018;43(8):836-840. doi: 
10.11771753193418786947.) concluded there was no statistically significant difference in 3-year 
recurrence rates between collagenase injection and needle fasciotomy (P-value >0.05).  
Stromberg et al. (J Hand Surg A. 2016;41(9):873-880. doi: 10.1016/j.jhsa.2016.06.014.) found 
similar 1-year recurrence rates in the treatment of MCP joint Dupuyten’s contractures with 
collagenase injection and needle fasciotomy (P-value >0.05). Skov et al. (J Hand Surg Am. 2017; 
42(5):321-328.e3. doi: S0363-5023(16)30817-6.) concluded collagenase injection and needle 
fasciotomy had similar 1-year recurrence rates in the treatment of PIP joint Dupytren’s 
contractures (P-value >0.05). 
 
Conclusions: Based on the analysis of three randomized controlled trials, there is no significant 
difference in the rate of contracture recurrence between CCH injection and PNF at the 1 and 3-
year follow-up mark. Variability among the treated joint and digit among the reviewed studies 
and non-blinding of evaluators may have impacted these results. Given the similarities in 
recurrence rates, it may be beneficial if future studies are directed toward other patient-oriented 
outcomes: associated healthcare cost, adverse events, visits required, and patient satisfaction. 
 




Dupuytren’s disease (DD) is a benign, slow-progressing, condition characterized by the 
formation of fibrous cords in the palmar fascia that causes flexion contractures of the digits. 
These contractures can impede normal hand function by causing deficits in the normal range of 
extension in single, or multiple digits. Often the joints of the hand are affected including the 
metacarpophalangeal (MCP), proximal interphalangeal (PIP), and the distal interphalangeal 
(DIP) joint. Given the gradual progression of this disease, the prevalence of DD increases with 
age. The overall prevalence of Dupuytren’s disease in Western populations is 12% in those aged 
55 and 29% in those aged 75 years old.1 The annual incidence in the U.S.  is approximately 3 
cases per 10,000 adults.2 DD is the most common hereditary connective tissue disorder and has a 
higher pervasiveness in patients with comorbidities such as hypertension, diabetes, ischemic 
heart disease, COPD, hyperlipidemia, and rheumatoid arthritis.3 In addition to the known strong 
genetic predisposition of DD, there are environmental risk factors, such as smoking, alcohol use, 
and previous hand injuries. As the number of those afflicted by such diseases within the United 
States continues to rise, so does the necessity for providers to be knowledgeable in the aspects of 
Dupuytren’s disease and its treatment. Physician Assistants may evaluate a Dupuytren’s patient 
upon initial presentation and contribute throughout their care, rendering this common disease 
pertinent to the practicing PA. 
 In the matter of cost, an exact number for the total healthcare cost of DD has not been 
identified. However, in 2019 the cost of treatment for a single finger contracture ranges from 
$7,657-8,519.2 It has also been shown that those with DD utilize more medical services such as 
physical therapy, ED visits, outpatient surgery, etc.4 There is not a precise estimate available 
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regarding how many healthcare visits are DD related; however, in 2014, 3 million Dupuytren’s 
patients suffered a contracture severe enough to warrant a procedure.1 
The etiology of DD is unknown; however, it involves fibroblastic and collagen deposition 
in the palmer fascia which produces cord-like structures. The 4th and 5th digit is commonly 
affected first, sparing the index finger and thumb. Men typically exhibit symptoms earlier than 
women and may include the development of a painless nodule of the palm, dimpling, or 
puckering of the skin. Loss of active and passive extension sequentially develops over time 
producing an abnormal curvature of the fingers and the inability to fully straighten the hand. 
Depending on the severity of the contracture, a patient’s quality of life and the ability to perform 
daily tasks can be greatly impacted. There is no known cure for DD and the recurrence of these 
hand contractures frequently occurs. 
The modalities used to treat Dupuytren’s disease include physical therapy, glucocorticoid 
injection, collagenase Clostridium histolyticum (CCH) injection, percutaneous needle fasciotomy 
(PNF), and open fasciotomy. These treatments all play a role at certain stages of the disease, 
however, once an extension deficit reaches 20 degrees or more, a procedure is typically 
warranted to correct the contracture. 
In 2009, CCH became the newest, non-surgical treatment aimed at enzymatically 
disrupting the palmar cords to release the contracture.5 The procedure involves injecting CCH 
into a palpable cord, followed by passive extension manipulation one day later to disrupt the 
cord. Prior to the introduction of CCH, percutaneous needle fasciotomy was the widely accepted 
inexpensive, minimally invasive technique for contracture release. Being minimally invasive, 
both CCH and PNF are treatment options that have the benefit of causing less tissue damage than 
open fasciotomy, yet overall are considered less effective in comparison. 




The objective of this selective EBM review is to determine whether or not collagenase 
injection decreases recurrence rates greater than percutaneous needle fasciotomy in the treatment 
of Dupuytren’s contracture. 
METHODS 
Studies compared in this review include three randomized controlled clinical trials that 
analyzed the efficacy of CCH injection against PNF in the treatment of Dupuytren’s 
contractures. The population being studied included adult patients with a single Dupuytren’s 
contracture who received the intervention of either CCH or needle fasciotomy. Patient outcomes 
included one, and three-year recurrence rates of contractures.  
Keywords used to search for these studies included “Dupuytren’s contracture”, “needle 
fasciotomy”, “collagenase injection” and were found via Cochran and PubMed databases. These 
peer-reviewed articles were selected by their relevance to the proposed topic, the inclusion of 
patient-oriented outcomes, and fulfillment of inclusion criteria. All three articles were published 
in English. Inclusion criteria consisted of studies that were randomized control trials, written in 
English, and conducted in adult patients. Exclusion criteria included studies published before 
2010, pediatric patients, and secondary research. Additional inclusion and exclusion criteria may 
be found in Table 1. Statistics reported and utilized in this EBM review include relative risk 
reduction (RRR), absolute benefit increase (ABI), numbers needed to treat (NNT), and p-values. 
OUTCOMES MEASURED 
 
The outcomes measured for this EBM review are the recurrence of a contracture post-
treatment or needing an additional procedure after initial therapy. All three studies defined 
recurrence as a passive extension deficit (PED) that measured greater than 20-30 degrees or more
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using a goniometer. Measurements were performed by either a nurse or physiotherapist at the 1 
or 3-year follow up mark.5-7 
Table 1. Demographics & Characteristics of Included Studies 
Study  Type # Pts Age 
(years) 
 
Inclusion Exclusion W/D Interventions 
Scherman 
(2016)  
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cord, extension 
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extension deficit 
of 20 degrees or 
more, well-
defined cord, 
PIP joint  
Allergies to 
CCH, not able 
to participate in 















Scherman et al. (2018) were the authors of a two-center randomized control trial that 
investigated the recurrence rate of treated primary DD contractures after 3 years.5 This was a 
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continuation from a previous RCT performed by the same authors in 2016.5 It compared the use 
of PNF to collagenase injection in the treatment of Dupuytren’s contractures, with evaluations 
being performed at 3 months, and 1-year.5 Patients were considered for this study if they: were 
diagnosed with primary Dupuytren’s disease, had a palpable cord, and a PED between 30 and 
135 degrees.5 Exclusion criteria included involvement of the thumb and an extension deficit less 
than 30 degrees.5 The digit treated varied upon the extent of contracture, with the most severe 
digit being selected for the procedure.5 Patients randomized to CCH injection underwent the 
procedure according to standard manufacturer protocols and returned to the procedure 24-72 
hours later to receive manipulation.5 This was performed with the use of a median, or ulnar nerve 
block.5 Those who were randomized to PNF treatment were brought to a treatment room where 
aseptic technique was used to perform subdermal injection and perforation of the cord with a 19-
gauge needle.5 Local anesthetic was administered for pain control. A total of 40 digits were 
treated with CCH injection, and 46 with needle fasciotomy.5 After 3 years only 40 of the needle 
fasciotomy group, and 36 of the CCH group were available for follow up.5 One patient from each 
group died and the remaining patients lost to follow up had been retreated prior to the 3-year 
mark.5 
 Scherman et al. defined recurrence of an increase in the PED of 30 degrees or more from 
the 3-month evaluation point, or if the patient had been retreated.5 Of the 36 CCH injection 
patients available for follow up, 12 had a recurrence compared to 17 of the 40 PNF treatment 
group. Based on these outcomes, there was no proven statistically significant difference found in 
the recurrence rate between CCH injection and needle fasciotomy. The reported calculated P-
value demonstrates this at 0.65, with the set value of significance at <0.05. 
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Table 2. 3 Year Recurrence Rate of CCH vs. PNF Treatment (Data from Scherman et al.5) 






Recurrence Rate * 12 17 0.65** 
*Recurrence is defined as a passive extension deficit of greater than 30 degrees of 
the treated joint or needing retreatment prior to 3-year follow up.  
**Significant P-Value <0.05. 
 
Table 3. 3 Year Contracture Prevention Outcomes Post CCH/PNF Treatment (Data from 
Scherman et al.5) 
Experimental Event Rate (EER) .333 
Control Event Rate (CER) .425 
Relative Risk Reduction (RRR) .214 
Relative Benefit Increase (RBI) .091 
Numbers Needed to Treat (NNT) 11. 
 
Stromberg et al. (2016) conducted a single-blinded, single-center, randomized study on a 
patient population totaling one hundred and forty patients with a single digit contracture 
involving the MCP joint.6 Patients were enrolled if they had a contracture greater than 20 degrees 
in the affected finger and met the additional inclusion/exclusion criteria seen in Table 1. The 
purpose of this study was to compare the efficacy of CCH to PNF. 69 patients were randomized 
to CCH injection, 71 to needle fasciotomy.6 Randomization was done via computer-generated 
randomization.6 CCH injection was performed in an outpatient procedure center, under sterile 
conditions and according to manufacturer instructions.6 Once the injection was complete, the 
hand was bandaged, and patients were instructed to avoid using the hand until the following day. 
Patients returned to the clinic the next day for the treated finger to be manipulated under local 
anesthesia to disrupt the cord.6 The treatment protocol for needle fasciotomy included sterile 
preparation of the hand, administration of local anesthesia, followed by repetitive movements of 
the needle through the cord until rupture was achieved.6 These procedures were performed by a 
single hand surgeon. Both treatment groups received teaching on passive extension exercises to 
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use at home.6 Follow-up was performed at 1 week and 1 year where a single physiotherapist 
examined and measured post-treatment extension deficits with a goniometer.6 For continuity 
within this EBM review, only 1-year results will be examined. After 1 year only two patients 
were lost to follow up, both belonging to the CCH treatment group.6 One patient cited moving as 
the barrier to follow up, the other simply declined participation.6 This study defined recurrence as 
a passive extension deficit greater than 20 degrees post-treatment.6 One patient from each 
treatment group experienced a recurrence of their contracture at the 1-year mark after an initial 
deficit of fewer than 5 degrees had been achieved.6 
Based on the treatment results in this study there was no statistically significant 
difference in outcomes between these two treatment groups. This can be shown by a p-value of 
>0.05. In addition to a non-significant p-value, the numbers needed to treat was calculated to be 
1000 (NNT:1000) demonstrating a small net effect in the prevention of contracture recurrence. 
Table 4. Recurrence Rate at 1-Year Follow-up between CCH and PNF (Data from 
Stromberg et al.6) 

















*Recurrence is defined as a passive extension deficit of greater than 20 degrees of the treated 
joint. 
**Significant P-Value <0.05 
 
Table 5. 1 Year Contracture Prevention Outcomes Post-CCH, PNF Treatment  
(Data from Stromberg et al.6) 
Experimental Event Rate (EER) .017 
Control Event Rate (CER) .016 
Relative Risk Reduction (RRR) .059 
Relative Benefit Increase (RBI) .001 
Numbers Needed to Treat (NNT) 1000. 
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Skov et al. (2017) performed a study that compared the treatment of PIP joint 
contractures by PNF or CCH injection. This was a single-center, independent, randomized 
controlled trial that followed fifty patients over two years to determine the efficacy of these 
treatment modalities in DD.7 Patients were determined eligible for inclusion in the study 
provided they had a PIP joint contracture with a PED deficit of 20 degrees or more, were 18 
years or older, and met the additional inclusion/exclusion criteria available in Table 1.7 This 
study group was similar regarding baseline characteristics, however, digits that were affected 
varied. 21 patients were randomized to PNF, 29 to CCH injection.7 Randomization of treatment 
was accomplished by having patients draw envelopes that were prepared using a randomization 
algorithm.7 Percutaneous needle fasciotomy was performed by prepping the hand with a topical 
disinfectant, sterile draping, administration of local anesthetic followed by repetitive perforation 
of the cord with a 25-gauge needle.7 This is performed at a slow pace while using passive 
extension to appropriately visualize the cord and avoid nerve damage. CCH injection was 
administered under the same sterile conditions according to the manufacturer’s guidelines.7 
These patients returned the next day for manipulation to disrupt the cord. All patients were given 
instructions to remove bandages after 24 hours and were fitted for an orthotic device to wear at 
night during the first 4 months.7 Study participants were instructed to follow up in 30 days, 1 
year, and 2 years for evaluation and clinical measurements performed by a nurse.7 Measurement 
of PED was performed with a goniometer. At 1-year post-treatment, 3 patients were lost to 
follow up in the CCH treatment group. All PNF patients were seen after 1 year for examination.7 
This study used a PED measurement of 20 degrees or more to define a recurrence of contracture. 
While data is available for the evidence of contracture recurrence at 30 days, 1 year and 2 years, 
only the 1-year results will be examined for this review. Between the two treatment groups, 65% 
Cawley | CCH Injection vs. PNF 8 
 
of those treated with CCH had contracture recurrence, compared to 57% who received PNF.7 
This demonstrates a similar rate of recurrence after being treated with either CCH or PNF. The 
statistical significance of these results can be deemed non-significant, denoted by the P-value of 
.56, indicating a small treatment effect.7 
Table 6. 1 Year Recurrence Rate of CCH vs. PNF Treatment (Data from Skov et al.7) 
Outcome  CCH  PNF P-Value  
Contracture Recurrence* (n=47) (95% CI) 65% (46-85) 57% (35-79) .56** 
*Recurrence is defined as a passive extension deficit >20 degrees 
** Significant P-Value <0.05 
 
Table 7. 1 Year Contracture Prevention Outcomes Post-CCH, PNF Treatment (Data from 
Skov et al.7) 
Experimental Event Rate (EER) .650 
Control Event Rate (CER) .570 
Relative Risk Reduction (RRR) .140 
Relative Benefit Increase (RBI) .08 




 Dupuytren’s disease is a common connective tissue disorder that is irreversible. The 
resulting contractures may lead to a patient’s impaired ability to perform the tasks of everyday 
life. Things such as perform certain occupations, prepare food, write with a pen, or button a 
sweater. While there are treatments available, there is currently no cure for the disease. Due to 
the high recurrence rates of these contractures, recurrence is a noteworthy area of research and a 
valid outcome for patients to consider when deciding among the various treatments for DD. All 
three studies used in this review compared CCH injection to PNF on adult patients with a 1, or 3-
year follow up. Of the three RTCs reviewed, all authors reported a p-value >0.05. This 
demonstrates no statistically significant difference between these two treatments in the rate of 
contracture recurrence. 
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A limitation seen within this review is the variance of digits and joints being treated in 
these studies. Stromberg et al. exclusively enrolled patients with an MCP contracture, Skov et al. 
selected those with PIP contractures, and Scherman et al. accepted a combination of the two.5-7 
This may pertinent due to the understanding that PIP joints and ulnar digits are more resistant to 
treatment. Another limitation was the lack of blinding in the individuals assessing a patient post-
treatment. Stromberg et al. was the only study where the physiotherapist performing clinical 
measurements was blinded to which procedure the patient received.6 Other limitations include 
small sample size, variability when performing clinical measurements, and non-blinding to 
treatment. 
Collagenase injection is a new, FDA approved non-surgical treatment designed to 
weaken the fascial cords causing the contracted digits. CCH has become increasingly used in the 
treatment of Dupuyten’s contractures and is available throughout the U.S. and Europe, marketed 
under the name Xiapex. While there is good evidence for the efficacy of CCH injection in 
reversing extension deficits, its cost-effectiveness should be taken into consideration. During the 
trial Stromberg et al. performed, the overall cost of CCH injection is $1,410, compared to $530 
for needle fasciotomy.6 Along with the proposed increase in cost, CCH injection requires a 
second clinic visit for manipulation, which may be burdensome to patients. Needle fasciotomy 
has been the standard minimally invasive treatment modality, is less costly than CCH injection; 
however, it poses a slightly increased risk of nerve damage.6 As with most injection procedures 
such as CCH and PNF, adverse events may include infection, nerve damage, bleeding, and 
hematoma formation.  






 Based on the analysis of three randomized controlled trials, there is no significant 
difference in the rate of contracture recurrence between CCH injection and PNF. All three 
studies concluded there was no outcome difference, in terms of recurrence rates when compared 
against each other during clinical trials. Future studies may be improved by increasing sample 
size, and blinding evaluators to the patient’s mode of treatment to prevent bias. Contracture 
recurrence is a valid outcome to consider when deciding on a treatment plan for DD. However, 
exploring other patient-oriented outcomes such as cost, risk of adverse events, number of visits 
required, and patient satisfaction may be more advantageous in the comparison of CCH to PNF.  
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